Showing results (181-190 of 203) with videos related to

Sort By:
Pageof 21
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2005
Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft modelsDebra Ferguson, Luis E Rodriguez, Joann P Palma, et al.
Molecular Cancer Therapeutics|August 28, 2020
Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody-Drug ConjugateMark G Anderson, Hugh D Falls, Michael J Mitten, et al.
Pharmacology|July 26, 2017
A "Prozone-Like" Effect Influences the Efficacy of the Monoclonal Antibody ABT-700 against the Hepatocyte Growth Factor ReceptorKedar S Vaidya, Anatol Oleksijew, Lora A Tucker, et al.
Kidney International|March 6, 2024
Apolipoprotein E is enriched in dense deposits and is a marker for dense deposit disease in C3 glomerulopathyBenjamin Madden, Raman Deep Singh, Mark Haas, et al.
Cancer Research|October 28, 2025
ABBV-303 is a Natural Killer Cell Engager Specific for c-Met-Expressing TumorsJennifer D Stone, Kamonwan Fish, Devika Ashok, et al.
Pediatric Surgery International|August 16, 2023
Long-term urological outcome of cloaca patients with multidisciplinary managementC Pellegrino, M Agamennone, B D Iacobelli, et al.
Molecular Cancer Therapeutics|June 9, 2023
ABBV-184: A Novel Survivin-specific TCR/CD3 Bispecific T-cell Engager is Active against Both Solid Tumor and Hematologic MalignanciesAdam S Chervin, Jennifer D Stone, Iwona Konieczna, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2009
ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumorsJoann P Palma, Yi-Chun Wang, Luis E Rodriguez, et al.
Molecular Cancer Therapeutics|March 4, 2015
Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal AntibodyEdward B Reilly, Andrew C Phillips, Fritz G Buchanan, et al.
Cancer Research|May 17, 2018
LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug ConjugatesJames W Purcell, Sonia G Tanlimco, Jonathan Hickson, et al.
Pageof 21